593 related articles for article (PubMed ID: 23473811)
1. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: the use of PANSS total score and clinical utility.
Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
Schizophr Res; 2013 May; 146(1-3):144-52. PubMed ID: 23473810
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale.
Pilla Reddy V; Kozielska M; Johnson M; Mafirakureva N; Vermeulen A; Liu J; de Greef R; Rujescu D; Groothuis GM; Danhof M; Proost JH
J Clin Psychopharmacol; 2013 Dec; 33(6):731-9. PubMed ID: 24113674
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia.
Harvey RC; James AC; Shields GE
CNS Drugs; 2016 Jan; 30(1):27-39. PubMed ID: 26801655
[TBL] [Abstract][Full Text] [Related]
5. Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials.
Pilla Reddy V; Kozielska M; Johnson M; Suleiman AA; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
Clin Pharmacokinet; 2012 Apr; 51(4):261-75. PubMed ID: 22420580
[TBL] [Abstract][Full Text] [Related]
6. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M
J Clin Psychiatry; 2004 Apr; 65(4):551-6. PubMed ID: 15119920
[TBL] [Abstract][Full Text] [Related]
7. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
[TBL] [Abstract][Full Text] [Related]
8. Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents.
Glick ID; Lemmens P; Vester-Blokland E
Int Clin Psychopharmacol; 2001 Sep; 16(5):265-74. PubMed ID: 11552769
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
10. Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics.
Szegedi A; Verweij P; van Duijnhoven W; Mackle M; Cazorla P; Fennema H
J Clin Psychiatry; 2012 Dec; 73(12):1533-40. PubMed ID: 23290326
[TBL] [Abstract][Full Text] [Related]
11. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
Kishi T; Iwata N
CNS Drugs; 2013 Sep; 27(9):731-41. PubMed ID: 23812802
[TBL] [Abstract][Full Text] [Related]
13. Optimization of maintenance therapy of Risperidone with CYP2D6 genetic polymorphisms through an extended translational framework-based prediction of target occupancies/clinical outcomes.
Li HQ; Xu JY; Gao YY; Jin L
Pharmacol Res; 2018 Nov; 137():135-147. PubMed ID: 30281999
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia.
Kozielska M; Pilla Reddy V; Johnson M; de Ridder F; Vermeulen A; Liu J; Groothuis GM; Danhof M; Proost JH
Schizophr Res; 2013 May; 146(1-3):53-8. PubMed ID: 23434198
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
Rosenheck RA; Leslie DL; Sindelar J; Miller EA; Lin H; Stroup TS; McEvoy J; Davis SM; Keefe RS; Swartz M; Perkins DO; Hsiao JK; Lieberman J;
Am J Psychiatry; 2006 Dec; 163(12):2080-9. PubMed ID: 17151158
[TBL] [Abstract][Full Text] [Related]
16. Cerebral cortical gray expansion associated with two second-generation antipsychotics.
Garver DL; Holcomb JA; Christensen JD
Biol Psychiatry; 2005 Jul; 58(1):62-6. PubMed ID: 15992524
[TBL] [Abstract][Full Text] [Related]
17. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis of the efficacy of second-generation antipsychotics.
Davis JM; Chen N; Glick ID
Arch Gen Psychiatry; 2003 Jun; 60(6):553-64. PubMed ID: 12796218
[TBL] [Abstract][Full Text] [Related]
20. Initial severity of the Positive and Negative Syndrome Scale (PANSS)-30, its main subscales plus the PANSS-6, and the relationship to subsequent improvement and trial dropout: a pooled participant-level analysis of 18 placebo-controlled risperidone and paliperidone trials.
Hieronymus F; Correll CU; Østergaard SD
Transl Psychiatry; 2023 Jun; 13(1):191. PubMed ID: 37286548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
